Long-term 36-month data from the Phase 1/2a trial of RG6501 (OpRegen) for geographic atrophy secondary to AMD will be presented at Clinical Trials at the Summit in June 2025.
Several therapies are under evaluation in clinical trials for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), addressing the unmet need for effective treatments.
Phase 1/2a trial results for RG6501 (OpRegen) demonstrate significant improvements in outer retinal structure within three months of a single administration in patients with geographic atrophy secondary to AMD.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.